Alector announces results from al002 invoke-2 phase 2 trial in individuals with early alzheimer's disease and provides business update

South san francisco, calif., nov. 25, 2024 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the invoke-2 phase 2 clinical trial evaluating the safety and efficacy of al002 in slowing disease progression in individuals with early alzheimer's disease (ad). treatment with al002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. however, al002 failed to meet the primary endpoint of slowing of alzheimer's clinical progression as measured by the clinical dementia rating sum of boxes (cdr®-sb), and there were no treatment effects that favored al002 on secondary clinical and functional endpoints. similarly, there were no significant effects on alzheimer's fluid biomarkers favoring al002, and amyloid pet imaging demonstrated no treatment-related reduction of brain amyloid levels. as previously reported, mri changes resembling amyloid-related imaging abnormalities (aria) and infusion-related reactions were observed in invoke-2. the instances of aria were primarily seen in participants treated with al002.
ALEC Ratings Summary
ALEC Quant Ranking